A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

Must have received: immunomodulatory drug (lenalidomide)

Subjects had received at least 1 prior lines of anti-myeloma therapy, which must include lenalidomide

Must have received: proteasome inhibitor (bortezomib, carfilzomib, ixazomib)

Subjects had received at least 1 prior lines of anti-myeloma therapy, which must include ... a proteasome inhibitor (bortezomib, carfilzomib or ixazomib)

Cannot have received: CD38 monoclonal antibody

Exception: primary refractory only

Subjects who are primary refractory to a prior CD38 monoclonal antibody therapy

Cannot have received: immunomodulatory drug (pomalidomide)

Previous exposure to pomalidomide

Cannot have received: chemotherapy

Subject has received chemotherapy or small molecule antitumor therapy within 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is shorter, before the first dose of study treatment

Cannot have received: biotherapy

Subject has received tumor biotherapy within 4 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is shorter, before the first dose of study treatment

Cannot have received: investigational agent

Subject has received investigational agents within 4 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is shorter (but not less than 14 days), before the first dose of study treatment

Cannot have received: stem cell transplant

Previous allogenic stem cell transplant or autologous stem cell transplantation (ASCT) before the first dose of study treatment